135 related articles for article (PubMed ID: 38432338)
41. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus.
Kim JH; Yoon YC; Kim YH; Park JI; Choi KU; Nam JH; Lee CH; Son JW; Park JS; Kim U
Clin Cardiol; 2024 Feb; 47(3):e24248. PubMed ID: 38436204
[TBL] [Abstract][Full Text] [Related]
44. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
[TBL] [Abstract][Full Text] [Related]
45. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
46. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
48. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
49. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
50. Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Lim J; Choi YJ; Kim BS; Rhee TM; Lee HJ; Han KD; Park JB; Na JO; Kim YJ; Lee H; Kim HK
Cardiovasc Diabetol; 2023 Jul; 22(1):188. PubMed ID: 37496050
[TBL] [Abstract][Full Text] [Related]
51. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
52. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
[TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
Singh AK; Singh A; Singh R
Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
[TBL] [Abstract][Full Text] [Related]
55. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Shao SC; Chang KC; Hung MJ; Yang NI; Chan YY; Chen HY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2019 Sep; 18(1):120. PubMed ID: 31551068
[TBL] [Abstract][Full Text] [Related]
56. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
[TBL] [Abstract][Full Text] [Related]
57. Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
Arbel R; Aboalhasan E; Hammerman A; Azuri J
Clin Drug Investig; 2020 Jul; 40(7):665-669. PubMed ID: 32449083
[TBL] [Abstract][Full Text] [Related]
58. Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Zheng XD; Qu Q; Jiang XY; Wang ZY; Tang C; Sun JY
Am J Cardiovasc Drugs; 2021 May; 21(3):321-330. PubMed ID: 33001355
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
60. Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes.
Edmonston D; Mulder H; Lydon E; Chiswell K; Lampron Z; Shay C; Marsolo K; Jones WS; Butler J; Shah RC; Chamberlain AM; Ford DE; Gordon HS; Hwang W; Chang A; Rao A; Bosworth HB; Pagidipati N
Am J Cardiol; 2024 Jun; 221():52-63. PubMed ID: 38641191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
